Charting the Decline of the Fourth Wave: US Overdose Deaths by Race, Geography, and Substance Involvement

Joseph R. Friedman, MD, PhD, MPH[1*], Joseph J. Palamar, PhD[2], Daniel Ciccarone, MD[3], Tommi L. Gaines, DrPH[4], Annick Borquez, PhD[4], Chelsea L. Shover, PhD[5], Steffanie A. Strathdee, PhD[4]

[1]Department of Psychiatry, University of California, San Diego, San Diego, CA
[2]Department of Population Health, NYU Grossman School of Medicine, New York, NY
[3]Department of Family Community Medicine, University of California, San Francisco, San Francisco, CA
[4]Department of Medicine, University of California, San Diego, San Diego, San Diego, CA
[5]Department of Medicine, University of California Los Angeles, Los Angeles, CA

*Correspondence to:
Joseph Friedman, MD PhD, MPH, University of California, San Diego, 200 W Arbor Dr, San Diego, CA, 92103. jofriedman@health.ucsd.edu

Word Count: 2,631 words
Keywords: fentanyl, fourth wave overdose crisis, overdose surveillance, polysubstance use, stimulants, substance use disorders

Abstract

Aims: To characterize decreases in overdose mortality in the United States between 2023 and 2024 by substance involvement, geography, race/ethnicity, demographic, and other key dimensions.

Design: Population-based study of national death records.

Setting: United States.

Participants/cases: All individuals who died from drug overdose between January 1999 and December 2024.

Measurements: Annual or monthly (annualized) overdose deaths per 100,000 population. Year and month of occurrence of overdose death; substance involvement; census region and division; state; county; race/ethnicity, age, and sex.

Findings: After over two decades of mostly exponential increases, monthly data show consistent decreases in overdose deaths between June 2023 and December 2024. Decreases reflected declining illicit fentanyl-involved deaths (with and without stimulants); however, increasing trends through 2024 were still seen in deaths involving stimulants without fentanyl, and those involving xylazine. Death rates in the Northeast, South and Midwest fell to 19.5, 19.4 and 17.3 per 100,000, respectively, in December 2024, but remained elevated in the West, compared with other regions, at 27.2 per 100,000. Non-Hispanic Black and African Americans had the largest decrease in death rates in 2023-2024 falling 29.3%, but remained elevated at 36.0 per 100,000, compared to the national average of 23.7 per 100,000. Non-Hispanic American Indian and Alaska Native individuals had the highest overdose mortality rate in 2024, at 50.8 per 100,000.

Conclusions

Recent decreases in overdose deaths are encouraging and unprecedented. Racial gaps remained large but shrunk by a modest margin. The geography of the overdose crisis has shifted, with the West now the most affected region, which may have implications for the targeting of funding. The nature of the crisis is also shifting, as stimulants and xylazine continue to represent increasingly important public health challenges, and renewed attention to nonfatal aspects of addiction in the US is needed.

Introduction

After decades of exponential increases, overdose death rates in the US have begun decreasing, drawing considerable public attention.(1) Earlier data described these trends at the national level,(2) with an overall downtrend beginning mid-year 2023.(3) However, more updated and detailed information is needed to inform prevention efforts, including how they differ by substance involvement, geography, race/ethnicity, and demographic categories.

Overdose deaths in the US have been characterized with a 'four wave' paradigm, wherein an escalating overdose crisis was attributed to shifting drug profiles over time.(4–6) The first wave was characterized by widespread access to prescription opioids—directly or indirectly through the healthcare system—leading to a surge in deaths involving commonly prescribed opioids.(7) As opioid deprescription limited access, in wave two, heroin filled the void left in the illicit opioid market, and heroin-involved deaths predominated.(8) Wave three involved the market takeover of illicitly-manufactured synthetic opioids, primarily fentanyls, whereby fentanyl-involved deaths came to represent the largest share of overdose mortality.(8) As fentanyl induced shifts in the illicit market and drug consumption behaviors, it ushered in the fourth wave, characterized by a rise in polysubstance overdose deaths, especially involving the combination of fentanyl with illicit stimulants such as cocaine and methamphetamine.(4,5) Deaths involving the combination of fentanyl with the veterinary sedative xylazine also increased during this period.(9,10)

These four waves of the overdose crisis have seen epidemiological differences by geography and race/ethnicity. Overdose death rates have historically been lower in the Western US, although the region has started to 'catch up' as illicit fentanyl arrived to the West.(11) The third and fourth waves of the overdose crisis have also driven sharp racial and ethnic inequalities in overdose, with Black and African Americans, as well as American Indian and Alaska Natives disproportionately affected.(12) One study found that mortality decreased among Non-Hispanic White individuals, but as of 2023, it was still increasing among the most affected racial/ethnic minority groups, suggesting widening disparities despite overall gains at the population level.(3) More recent evidence is needed to evaluate if racial/ethnic minority communities are now experiencing similar decreases in overdose trends.

Here, we leverage recent records to describe overdose trends between January 1999-December 2024 to assess trends by substance-involvement, race/ethnicity, geography and demographics.

Methods

Nationally representative drug overdose death data from the National Vital Statistics System (NVSS) were obtained for the 1999-2024 period stratified by year, month, race/ethnicity, geography, and substance-involvement via the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for Epidemiologic Research (WONDER) platform.(13) Drug overdose deaths were defined by ICD-10 underlying cause of death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined intent).(13) Recorded deaths from

2024 were provisional and may slightly underestimate finalized records, whereas records from 2023 and prior were finalized.

Substance involvement was characterized using ICD-10 multiple cause of death codes including prescription opioids (T40.2), heroin (T40.1), synthetic opioids (primarily and herein referred to as fentanyl) (T40.4),(5) cocaine (T40.5), psychostimulants with abuse potential (primarily and herein referred to as methamphetamine) (T43.6),(14) and xylazine (T42.7 or T46.5).(9) Of note, T40.4 and T43.6 represent umbrella codes for 'Other Synthetic Narcotics' and 'Psychostimulants with Abuse Potential' respectively, which are widely used in epidemiological research to represent illicit fentanyl and methamphetamine, respectively, as they mostly code for these substances.(9,14,15) For simplicity, we use the terms 'fentanyl' and 'methamphetamine' throughout the text. Nevertheless, a small number of other substances (such as nitazenes or U-compounds, in the case of T40.4) are also represented by these codes. All analyses were conducted in R version 4.4.1.

Results

Overdose mortality has been characterized by a shifting profile of drugs over time. Figure 1 provides a simplified schema representing the four waves of the US overdose crisis. The contributions of prescription opioids, heroin, and fentanyl without, and with stimulants (roughly corresponding to waves 1-4 of the overdose crisis, respectively)(5) are declining in the latest data. Mortality rates for overdose deaths involving prescription opioids and heroin (with fentanyl co-involved deaths omitted) reached inflection points and began to fall in 2016 and 2015, respectively, marking the decline of waves one and two of the crisis. Overdose mortality

rates involving illicit fentanyl without stimulant co-involvement began to fall in 2022, marking the decline of wave three of the overdose crisis. Overdose death rates involving fentanyl with stimulants declined for the first time in 2024, beginning the decline of wave four. Deaths involving methamphetamine (without fentanyl co-involvement) and cocaine (without fentanyl co-involvement) continued increasing between 2023 and 2024, consistent with an overall trend of increasing stimulant-related deaths. Deaths involving xylazine also represented an increasing proportion of fentanyl-involved deaths between 2023 and 2024, rising from being co-involved in 8.3% of fentanyl-involved overdose deaths in 2023 to 12.6% of fentanyl-involved deaths in 2024.

The overall decrease in overdose deaths in the US in 2023-2024 has been largely driven by declines in deaths involving illicit fentanyl (Figure 2). Fentanyl-involved deaths without and with stimulants dropped from 31,193 and 41,583 in 2023 respectively to 19,673 and 28,062 respectively in 2024. In contrast, the number of deaths involving stimulants, without fentanyl, grew from 18,142 in 2023 to 18,907 in 2024, representing 17.3% of all overdose deaths in 2023, and 23.8% of overdose deaths in 2024 (Figure 2).

Decreases in overdose mortality also varied by race/ethnicity and other demographic factors (Figure 3). Averaging across all racial groups, overdose death rates fell by 24.4% between 2023 and 2024, to 23.7 per 100,000. Non-Hispanic Black and African Americans had the largest decrease in overdose death rates between 2023 and 2024 of any group assessed, falling 29.3%. Nevertheless, this group had an overdose death rate in 2024 of 36.0 per 100,000, representing a rate 1.51 times the national average. Non-Hispanic American Indian and Alaska Native

individuals had the highest overdose mortality rate of any group assessed in 2024, at 50.8 (representing 2.15 times the national average rate), and experienced below-average decreases between 2023 and 2024, of 20.1%. Non-Hispanic White individuals had approximately average overdose death rates in 2024 of 24.8 (1.04 times the national average) and saw year-over-year percent decreases (23.9%) similar to the national average.

Racial inequalities differed sharply by substance-involvement (Figure 4). The first wave of the overdose crisis, represented by overdoses involving prescription opioids without fentanyl, disproportionately affected Non-Hispanic White and Non-Hispanic American Indian and Alaska Native individuals, with overdose death rates 1.36 and 1.59 times respectively above the national average for this drug in 2024. Wave two, representing heroin without fentanyl, had mostly subsided by 2024, for all groups assessed. Wave three, represented by fentanyl without stimulants, has disproportionately affected Non-Hispanic Black and Non-Hispanic American Indian and Alaska Native individuals, with overdose death rates 1.48 and 2.09 times respectively above the national average in 2024. Similarly Wave 4, among deaths involving fentanyl with stimulants, Non-Hispanic Black and Non-Hispanic American Indian and Alaska Native individuals, had overdose death rates 1.67 and 2.30 times respectively above the national average in 2024. Cocaine-involved overdose deaths (with fentanyl deleted) have disproportionately affected Non-Hispanic Black and African Americans for all years assessed, with this disparity rising to 3.13 times the national average by 2024. Methamphetamine-involved deaths (with fentanyl deleted) have disproportionately affected Non-Hispanic American Indian and Alaska Native individuals, with an overdose rate 3.24 times above the national average in 2024. Xylazine-involved

overdose deaths disproportionately affected Black and African Americans, with a rate of 1.66 times the national average in 2024.

Relative decreases in overdose death rates between 2023 and 2024 were slightly higher among males than females, with 25.7% and 21.1% decreases, respectively (Figure 3). The largest percent decreases in overdose death rates were seen among individuals aged 15-24 (35.7% decrease) and 25-34 years (31.9% decrease). Older individuals generally had smaller decreases, and individuals aged ≥75 experienced a small increase (of 2.9%) during this time period.

Overdose mortality decreased differentially by region. In 2018, the Northeast had the highest overdose death rates, followed by the South and Midwest, with the West considerably lower (Figure 5). In 2024, overdose mortality in the West definitively surpassed that of other regions. Death rates in the Northeast, South and Midwest fell to 19.5, 19.4 and 17.3 per 100,000 respectively in December 2024, whereas in the West they remained more elevated, at 27.2 per 100,000 in December 2024. Between 2023 and 2024 death rates fell by 28.7% in the Northeast, 28.2% in the Midwest, and 26.5% in the South, compared to 14.7% in the West (Figure 3).

Among Census divisions, the largest decreases between 2023 and 2024 were observed in East North Central (which includes Illinois, Indiana, Michigan, Ohio, and Wisconsin) with a 30.5% decline, and the South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, and Washington, D.C.) with a decline of 29.2% (Figure 3). The smallest decreases were observed in the Mountain Division (including Arizona, Colorado, Idaho,

Montana, Nevada, New Mexico, Utah, and Wyoming) with 9.7% and the Pacific (Alaska, Hawaii, California, Oregon, and Washington) with 17.2%. Among states, the largest decreases during this period were observed in West Virginia (40.4% decrease), Virginia (29.7% decrease) and Delaware (32.7% decrease) [Figure 3; Figure 6]. Hawaii and South Dakota were the only states to register an increase in overdose mortality between 2023 and 2024. (4.0% and 3.1% increases, respectively), and Utah and Nevada experienced modest decreases (2.7% and 3.5% respectively; Figure 6). In 2024, the highest overall overdose death rates were in Washington, D.C. (46.4 per 100,000) and West Virginia (46.4 per 100,000) whereas Nebraska (7.8 per 100,000), South Dakota (10.7 per 100,000), and Iowa (13.3 per 100,000) had the lowest rates. Among the ten counties with the largest numbers of deaths in 2024, Wayne County, Michigan (home to Detroit) and Cook County, Illinois (home to Chicago) had the largest relative decreases (41.6% and 30.3%, respectively). Clark County, Nevada (home to Las Vegas) saw a small increase in deaths (3.0%) and Maricopa County, Arizona (home to Phoenix) experienced the smallest decrease of 3.6%.

Discussion

After decades of exponential growth, the US is in the midst of a historic moment in the trajectory of the overdose crisis, as mortality rates decreased steadily between mid-2023 through the end of 2024. Although the beginning of these downward trends was previously reported,(3) here we provide newfound details documenting the continued trajectory, significance, and profundity of these changes. We show that in 2024, for the first time, wave four of the crisis (defined by fentanyl in combination with stimulants), is also decreasing in

magnitude. We also highlight that not all segments of the US overdose crisis are shrinking. Fatalities involving stimulants and xylazine have grown and continue to represent important public health challenges. Importantly, other novel substances, such as medetomidine, nitazenes, designer benzodiazepines, and carfentanil have emerged in hotspots across the country.(10,16–19)

Our findings also suggest that stimulants and xylazine continue to represent growing challenges. Cocaine- and methamphetamine-involved deaths increased in recent years and represent a growing share of all overdose fatalities. Other stimulant-related health harms such as substance-induced psychosis, have also risen.(20) It is important to note that the majority of stimulant-related burden of disease stems from slower epidemiological processes compared to overdose, such as morbidity and accelerated mortality due to cardiovascular, neurovascular, pulmonary, and psychiatric consequences.(21) As stimulants continue to induce a growing share of addiction-related burden of disease, a focus on overdose mortality as the defining indicator of the public health impact of substance use disorders may be increasingly insufficient. Instead, more comprehensive measures such as disability adjusted life years (DALYS)(21) that account for morbidity may more completely reflect the trajectory of the US addiction crisis.

Recent decreases in overdoses have not occurred equally by geography, and some marked reversals of prior trends were observed. After decades of being the least affected region, overdose deaths are now the highest in the Western US. This may reflect the lagged course of the overdose crisis in the West, with the region trailing behind the rest of the country in

225 decreases. Alternatively, it may reflect other unique dynamics in the Western region of the US,
226 including distinct illicit drug supply lines, a higher availability of illicitly manufactured fentanyl
227 (especially in pill form), and hotspots with increasing fentanyl use.(18,22,23)
228
229 After several years of rapidly widening inequalities in race/ethnicity, 2024 showed some small,
230 albeit encouraging, decreases in disparities in overdose mortality, with Black and African
231 Americans having the largest relative decrease between 2023 and 2024, falling by nearly one-
232 third in a single year. Nevertheless, the magnitude of inequalities remains quite large. In
233 particular, the mortality rate among American Indian and Alaska Natives remained double that
234 of the general population. Importantly, the substances with overdose rates continuing to rise
235 through 2024—stimulants and xylazine—show marked racial inequalities, suggesting that
236 disparities may not decrease in future years without intervention. Policies targeting community
237 and system level factors associated with inequitable health will be needed to address these
238 persistent gaps.(12,24,25)
239
240 The decreases in overdose mortality in 2023-2024 in the US are likely multifactorial in nature,
241 reflecting several overlapping epidemiological and demographic phenomena.(3,26–29) Deaths
242 have now returned to pre-COVID pandemic levels, as numerous social, economic, and
243 epidemiological consequences of the pandemic have also begun to recede.(30) The availability
244 and use of the opioid overdose antidote naloxone have been considerably scaled up in recent
245 years, which is likely playing an important role(31,32). Some evidence suggests that shifts in the
246 illicit fentanyl supply are also key to driving recent dynamics, with lower potency and variability

247 of illicit opioids, and the inclusion of high rates of fillers and adulterants leading to a lower
248 overall opioid potency.(26,28,33) The widespread shift from injecting to smoking opioids has
249 also been associated with decreased overdose rates.(34,35) There are also likely a reduced
250 number of individuals that are susceptible to overdose, given increased awareness of the risks
251 of illicit fentanyl, and the premature mortality of a large segment of previously susceptible
252 individuals.(3,26,29) Some simulation modeling suggests that the decreases at-risk population
253 may be single most important driver(29), whereas other studies have suggested that sudden
254 decreases in the availability and/or potency of illicit fentanyl underpinned the abruptness of the
255 drop in deaths(28). Some of these observed trends may also simply reflect, at least in part, an
256 overall 'regression to the mean' as trends homogenize in the context of nearly universal
257 decreases. Examining demographic and geographic categories highlights that the states and
258 demographic groups with the highest mortality rates generally experienced the greatest
259 decreases. Further research is needed to assess the relative contribution of each of these
260 factors to the observed decreases, and guide continued prevention.
261
262 **Limitations**
263 Caution should be used in extrapolating from the gains achieved in 2024 to future decreases.
264 Due to inherent lags in overdose toxicology testing, the mortality records from 2024 are
265 provisional in nature and may change when final records are subsequently released.(36)
266 However, in previous years, differences between provisional and final trends have been
267 relatively small and have not changed the overall directionality of trends. Additionally, the

268 race/ethnicity categorizations used here have limitations, especially for American Indian and
269 Alaska Native individuals, which may mask the magnitude of inequalities(37).

270 **Conclusions**

271 Recent decreases in overdose deaths are encouraging and relatively unprecedented. Despite
272 recent progress, US overdose mortality remains a global outlier.(38) The country saw about
273 80,000 deaths in 2024. If the US population had the same overdose death rate as Western
274 Europe, about 9,000 lives would have been lost.(21) Greater investments are needed to
275 sustainably reverse the course of this large-magnitude, preventable mortality crisis, via
276 evidence-based approaches such as medications for opioid use disorder, harm reduction, and
277 access to addiction-related treatment.

278

279 Some encouraging, yet very early, improvements in racial/ethnic inequalities in overdose
280 mortality have also been seen, after profoundly worsening during the COVID-19 pandemic.(12)
281 Yet disparities remain, even as the national trend in deaths now declines. More progress can be
282 made with tailored solutions to reduce overdose deaths among the most affected groups.(12)

283

284 **Funding**

285 JRF received funding from the National Institute on Drug Abuse (1U01DA063078-01) and the
286 National Institute of Mental Health (MH101072). JP received support from the National Institute
287 on Drug Abuse of the National Institutes of Health (R01DA057289 and U01DA051126). DC was
288 supported by National Institute on Drug Abuse (R01DA054190). CLS was supported by National
289 Institute on Drug Abuse (R01DA057630; K01DA05771**).** AB was supported by National Institute

290 on Drug Abuse (R33DA061260 and DP2DA049295). Funders had no role in the design and
291 conduct of the study; collection, management, analysis, and interpretation of the data;
292 preparation, review, or approval of the manuscript; and decision to submit the manuscript for
293 publication.
294

295 **Conflicts of Interest**

296 JP reported receiving personal fees from the Washington-Baltimore High Intensity Drug
297 Trafficking Areas program, Elsevier, Wiley, Rutgers University, Arizona State University, the
298 University of Southern California, Queensland University, the National Network of Public Health
299 Institutes, Alta Mira Recovery programs, and Dartmouth University, and nonfinancial support
300 from NIH/NIDA, the University of Florida, Rx Summit, the American College of
301 Neuropsychopharmacology, and the Reagan-Udall Foundation for the FDA during the conduct of
302 the study. DC reports personal fees from Emergent Biosciences outside the submitted work. All
303 other authors declare no conflict of interest.



Figure 1. Simplified Representation of the Four Waves of the US Overdose Crisis
Based on the general approach from Friedman and Shover, the four waves of the US overdose crisis are shown in a simplified schema. Wave one is represented by prescription opioids (with fentanyl co-involvement deleted), wave 2 is shown by deaths involving heroin (without fentanyl). Wave 3 and 4 correspond to fentanyl-involved deaths without, and with, stimulants, respectively. Xylazine and stimulants without fentanyl are shown as examples of more recent drug trends that are not decreasing. Note that most xylazine-involved deaths also involve fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.



Figure 2. Overdose Deaths by Stimulant and Fentanyl Involvement
The total number of annual overdose deaths each year is shown by categories of fentanyl and stimulant involvement. Data from 2024 are provisional and may slightly underestimate final numbers.



Figure 3. Percent Change and Level of Overdose Deaths Between 2023-2024 by Race, Sex, Age, Geography
Top: percent change in overdose death rate is shown between 2023 and 2024 for several stratifying variables. A horizontal dashed line shows the national average decrease in overdose deaths for this period. Region and county refer to the geography of residence of each death, not occurrence location of the deceased. Data are shown from the 10 counties and 10 states with the highest total number of deaths in 2024. Bottom: the death rate per 100,000 in 2023 and 2024 is shown for the same stratifying variables. A horizontal dashed line shows the average overdose mortality rate in 2024. Data from 2024 are provisional and may slightly underestimate final numbers.



Figure 4. Overdose Deaths by Substance and Race/Ethnicity, 1999-2024
Overdose deaths per 100,000 population are shown separately by substance involvement and race/ethnicity between 1999 and 2024. Rx opioids without fentanyl, heroin without fentanyl, fentanyl without stimulants, and fentanyl with stimulants correspond roughly to waves 1,2,3 and 4, of the overdose crisis, respectively. Deaths involving xylazine, and stimulants without fentanyl, represent trends continuing to rise in 2024, despite overall decreases in death totals. Data from 2024 are provisional.



Figure 5. Monthly Overdose Mortality by Region, 2018-2024
The death rate per 100,000 people is shown by month and US Census Region. Monthly data are annualized by multiplying by 12 to reflect the magnitude of annual mortality rates. Monthly data for the entire US are also shown in Black. Data from 2024 are provisional and may slightly underestimate final numbers.



Figure 6. State-Level Percent Change and Level in Overdose Deaths, 2024
Top: the percent change in overdose deaths between 2023 and 2024 is shown for the continental US by state. State refers to the geography of residence of each death, not occurrence location of the deceased. States are classified according to quartiles of decreases in percent change, or increasing status, for a total of 5 categories. Bottom: the death rate per 100,000 population is shown by state for 2024, with quintiles shown by color. Data from 2024 are provisional and may slightly underestimate final numbers.

References

1. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018 [Internet]. Centers for Disease Control and Prevention; 2024. Available from: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm

2. Ahmad F, Cisewski J, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2025. [Internet]. 2020 Dec. Available from: https://dx.doi.org/10.15620/cdc/20250305008

3. Post LA, Ciccarone D, Unick GJ, D'Onofrio G, Kwon S, Lundberg AL, et al. Decline in US Drug Overdose Deaths by Region, Substance, and Demographics. JAMA Netw Open. 2025 June 12;8(6):e2514997.

4. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Current Opinion in Psychiatry. 2021 July;34(4):344–50.

5. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. Addiction. 2023;118(12):2477–85.

6. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018 Sept 21;361(6408):eaau1184.

7. Friedman J, Kim D, Schneberk T, Bourgois P, Shin M, Celious A, et al. Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California. JAMA Internal Medicine. 2019 Apr 1;179(4):469–76.

8. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019 Sept;71:183–8.

9. Friedman JR. Assessing an ICD-10 Code Approach for Estimating Xylazine-Involved Overdose Deaths in the United States. Drug and Alcohol Dependence. 2025 July;112781.

10. Gupta Rahul, Holtgrave David R., Ashburn Michael A. Xylazine — Medical and Public Health Imperatives. New England Journal of Medicine. 2023 June 14;388(24):2209–12.

11. Shover CL, Falasinnu TO, Dwyer CL, Santos NB, Cunningham NJ, Freedman RB, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. Drug Alcohol Depend. 2020 Nov 1;216:108314.

12. Friedman JR, Nguemeni Tiako MJ, Hansen H. Understanding and Addressing Widening Racial Inequalities in Drug Overdose. AJP. 2024 May 1;181(5):381–90.

13. CDC WONDER [Internet]. Available from: https://wonder.cdc.gov/

14. Han B, Cotto J, Etz K, Einstein EB, Compton WM, Volkow ND. Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. JAMA Psychiatry [Internet]. 2021 Jan 20 [cited 2021 Jan 23]; Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2774859

15. O'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1740–6.

16. Palamar JJ, Krotulski AJ. Medetomidine Infiltrates the US Illicit Opioid Market. JAMA. 2024 Nov 5;332(17):1425.

17. Samarasekera U. “Even worse than fentanyls”: nitazenes in the USA. The Lancet. 2024 Dec;404(10469):2250–1.

18. Friedman J, Ciccarone D. The public health risks of counterfeit pills. The Lancet Public Health. 2025 Jan 1;10(1):e58–62.

19. Ciccarone D. The Donovan Memorial Lecture: ‘Fentanyl-Plus’: A New Era of Fentanyl Polydrug Combinations in The North American Overdose Crisis. Journal of Medical Toxicology. 2025;In Press.

20. Calcaterra SL, Yamkovoy K, Swathi PA, Ciccarone D, Del Pozo B, Englander H, et al. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015-2019. Drug Alcohol Depend. 2024 Sept 1;262:111409.

21. Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024 May 18;403(10440):2100–32.

22. Palamar JJ, Fitzgerald N, Carr TH, Cottler LB, Ciccarone D. National and regional trends in fentanyl seizures in the United States, 2017–2023. International Journal of Drug Policy. 2024 May 13;104417.

23. Montero F, Bourgois P, Friedman J. Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine (“Tranq”), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. Journal of Illicit Economies and Development. 2022 Dec 2;4(2):204–22.

24. Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The Opioid Epidemic: a Crisis Disproportionately Impacting Black Americans and Urban Communities. J Racial and Ethnic Health Disparities. 2023 Aug;10(4):2039–53.

25. Bauer C, Hassan GH, Bayly R, Cordes J, Bernson D, Woods C, et al. Trends in Fatal Opioid-Related Overdose in American Indian and Alaska Native Communities, 1999–2021. American Journal of Preventive Medicine. 2024 June;66(6):927–35.

26. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths decreased? Widespread fentanyl saturation and decreased drug use among key drivers. The Lancet Regional Health – Americas [Internet]. [cited 2025 Oct 11]; Available from: https://doi.org/10.1016/j.lana.2025.101226

27. CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths [Internet]. 2025. Available from: https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html

28. Vangelov K, Humphreys K, Caulkins JP, Pollack H, Pardo B, Reuter P. Did the illicit fentanyl trade experience a supply shock? Science. 2026 Jan 8;391(6781):134–6.

29. Stringfellow EJ, Lim TY, Hasgul Z, Jalali MS. Structural Drivers of the Drop in Opioid Overdose Deaths in the US. JAMA Psychiatry [Internet]. 2025 Nov 26 [cited 2025 Dec 26]; Available from: https://doi.org/10.1001/jamapsychiatry.2025.3584

30. Friedman J, Akre S. COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States, January–July 2020. Am J Public Health. 2021 Apr 15;e1–8.

31. Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. The Lancet Public Health. 2022 Mar 1;7(3):e210–8.

32. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013 Jan 31;346:f174.

33. Shover CL, Koncsol AJ, Godvin ME, Goodman-Meza D, Pardo B, Poimboeuf M, et al. High variation in purity of consumer-level illicit fentanyl samples in Los Angeles, September 2023–April 2025. International Journal of Drug Policy. 2025 Nov 1;145:104977.

34. Eger WH, Abramovitz D, Bazzi AR, Bórquez A, Vera CF, Harvey-Vera A, et al. Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020–2023. Drug and Alcohol Dependence. 2024 June 1;259:111318.

35. Karandinos G, Unick J, Ciccarone D. Mortality risk among individuals who smoke opioids compared with those who inject: A propensity score-matched cohort analysis of United States national treatment data. Addiction. 2025 May 1;120(5):1040–5.

36. Spencer MR. Timeliness of Death Certificate Data for Mortality Surveillance and Provisional Estimates. CDC Vital Statistics Rapid Release. 2016;8.

37. Anderson RN, Copeland G, Hayes JM. Linkages to Improve Mortality Data for American Indians and Alaska Natives: A New Model for Death Reporting? Am J Public Health. 2014 June;104(S3):S258–62.

38. Gumas E. U.S. Overdose Deaths Remain Higher Than in Other Countries — Trend-Tracking and Harm-Reduction Policies Could Help [Internet]. Commonwealth Fund; 2025. Available from: https://www.commonwealthfund.org/blog/2025/us-overdose-deaths-remain-higher-other-countries-trend-tracking-and-harm-reduction?check_logged_in=1